Intel stock spikes after report of possible US government stake
Elevance Health Inc’s stock reached a 52-week low, hitting $274.33, significantly below its 52-week high of $567.26. According to InvestingPro analysis, the stock appears undervalued, with analysts setting price targets ranging from $297 to $507. This decline marks a significant downturn for the company, with the stock experiencing a 1-year change of -48.66%. Despite these challenges, the healthcare giant maintains strong fundamentals with a healthy 2.42% dividend yield and has consistently raised its dividend for 14 consecutive years. The company’s financial health score remains "GOOD" according to InvestingPro metrics. As the market continues to fluctuate, investors are closely watching Elevance Health’s performance and strategic responses to its current financial position. The company maintains a moderate debt level and shows promising profitability metrics. For deeper insights into Elevance Health’s valuation and growth potential, access the comprehensive Pro Research Report available on InvestingPro, which covers what really matters for informed investment decisions.
In other recent news, Elevance Health reported its second-quarter 2025 financial results, revealing adjusted earnings per share of $8.84, which matched consensus estimates. The company’s revenue reached $49.8 billion, approximately 2.8% above consensus, driven by increased pharmacy revenues and premiums per policy. Despite these results, Elevance reduced its earnings per share outlook by $4.50, translating to a reduction of about $1.3 billion in pre-tax income. Analyst firms have responded to these developments with varied adjustments to their price targets. UBS maintained its Buy rating on Elevance and set a price target of $435.00. Bernstein lowered its price target to $445.00 from $487.00, citing pressures from the Affordable Care Act (ACA) and Medicaid. TD Cowen, while maintaining a Buy rating, significantly reduced its price target to $330.00 due to pressures in the Health Insurance Exchange (HIX) and Medicaid segments. Additionally, Elevance Health appointed Steve Collis to its board of directors, effective August 1, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.